Understanding CDK4/6 Inhibitors in Breast Cancer: Biomarkers, Resistance, and the Emerging Role of Natural Compounds

Understanding CDK4/6 Inhibitors in Breast Cancer: Biomarkers, Resistance, and the Emerging Role of Natural Compounds

A Science-Based Look at Who Benefits, Why Some Tumors Resist, and What Integrative Support May Offer Over the past decade, CDK4/6 inhibitors—palbociclib, ribociclib, and abemaciclib—have transformed the treatment landscape for hormone receptor-positive, HER2-negative...

Pin It on Pinterest